Guggenheim reiterated a Buy rating on ANI Pharmaceuticals (NASDAQ: ANIP), and raised the price target to $80.00 (from $65.00), following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

ANI Pharma (ANIP) Tops Q2 EPS by 34c; Boosts FY16 OutlookAugust 4, 2016 8:43 AM ANI Pharmaceuticals Reports Record Second Quarter Results and Increases Full-year 2016 GuidanceAugust 4, 2016 8:30 AM Trading Radar for 8/4: Kellogg (K), MGM Resorts (MGM), Activision (ATVI), FireEye (FEYE), Weight Watchers (WTW) ReportAugust 3, 2016 2:51 PM